<span data-sheets-value="[null,2,"Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression."]" data-sheets-userformat="[null,null,641,[null,1],null,null,null,null,null,null,0,null,0]">Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.

Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.

Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.

Should EGFR TKI Therapy be Continued Beyond Progression?

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers.  The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

Science

Medicine

Health & Fitness

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

Share Should EGFR TKI Therapy be Continued Beyond Progression?

Sign up to save your podcasts

Should EGFR TKI Therapy be Continued Beyond Progression?

Should EGFR TKI Therapy be Continued Beyond Progression?